Provided by Tiger Trade Technology Pte. Ltd.

iShares U.S. Healthcare ETF

71.17
-0.2000-0.28%
Post-market: 71.15-0.0200-0.03%19:30 EDT
Volume:313.32K
Turnover:22.29M
Market Cap:3.85B
PE:6.41
High:71.44
Open:71.17
Low:70.93
Close:71.37
52wk High:74.59
52wk Low:56.44
Shares:54.15M
Float Shares:54.15M
Volume Ratio:0.34
T/O Rate:0.58%
Dividend:0.80
Dividend Rate:1.12%
EPS(TTM):11.10
EPS(LYR):3.06
ROE:6.01%
ROA:0.87%
PB:1.38
PE(LYR):23.26

Loading ...

Abbvie - Declares Qtrly Cash Dividend of $1.73 Per Share

THOMSON REUTERS
·
Sep 11

AbbVie’s Eye Implant Study Delivers Fresh Real‑World Clarity for Investors

TIPRANKS
·
Sep 11

Wachtell Dealmaker Jumps to Linklaters to Bolster US Buildout

Reuters
·
Sep 10

Johnson & Johnson Announces R$ 0.3 Per Unit Dividend for 3Q 2026

Reuters
·
Sep 10

Eli Lilly is Maintained at Reduce by HSBC

Dow Jones
·
Sep 10

Eli Lilly’s GLP-1 Windfall to Fund Push into Women’s Health - Bloomberg News

Reuters
·
Sep 10

2 Reasons Cooper Companies Stock is by Far the Worst in the S&P 500 Today

Dow Jones
·
Sep 10

AbbVie Says Atogepant Met Primary, Secondary Endpoints in Phase 3 Menstrual Migraine Study

MT Newswires Live
·
Sep 10

Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Thursday Amid Producer Price Inflation Data Release

MT Newswires Live
·
Sep 10

AbbVie’s atogepant shows positive Phase 3 results in menstrual migraine

TIPRANKS
·
Sep 10

Abbvie - Atogepant Safety Results Consistent with Known Profile; no New Safety Signals

THOMSON REUTERS
·
Sep 10

Abbvie - Atogepant Meets Primary and All Eight Ranked Secondary Endpoints in Phase 3 Luna Study

THOMSON REUTERS
·
Sep 10

Abbvie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine

THOMSON REUTERS
·
Sep 10

Abbvie - Atogepant Shows Significant Improvements Across Multiple Endpoints Versus Placebo

THOMSON REUTERS
·
Sep 10

Johnson & Johnson receives CE Marking for ACUVUE OASYS MAX

TIPRANKS
·
Sep 10

Johnson & Johnson Receives Ce Marking for Acuvue Oasys Max Reusable Contact Lenses

THOMSON REUTERS
·
Sep 10

HSBC Adjusts Price Target on Eli Lilly and Co. to $940 From $850, Keeps Reduce Rating

MT Newswires Live
·
Sep 10

'Cut Points' for 2027 Medicare Advantage Plans Look Neutral to Positive, Analysts Say

Reuters
·
Sep 10

Exchange-Traded Funds, US Equities Fall After Midday

MT Newswires Live
·
Sep 10

Sector Update: Healthcare

MT Newswires Live
·
Sep 10